The frequent mutation of the TRK FLT3-ITD in AML led to the clinical implementation of the small molecule TRK inhibitors sorafenib, midostaurin, gilteritinib which are currently tested in clinical trials with newly diagnosed pediatric AML patients carrying an FLT3 mutation [145,146]. The gene discussed is FLT3; the disease is acute myeloid leukemia.